HUTCHMED (LON:HCM) Reaches New 12-Month Low – Time to Sell?

Shares of HUTCHMED (China) Limited (LON:HCM) reached a new 52-week low during trading on Monday . The stock traded as low as GBX 189.98 ($2.45) and last traded at GBX 189.98 ($2.45), with a volume of 527242 shares changing hands. The stock had previously closed at GBX 218 ($2.81).

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 11.97, a quick ratio of 2.97 and a current ratio of 2.81. The company has a market cap of £2.06 billion, a PE ratio of -48.49 and a beta of 0.76. The business’s 50-day moving average is GBX 234.84 and its 200 day moving average is GBX 257.31.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).